Illumina's Q2 Revenues Climb 21 Percent; Stock Falls on Wall Street Miss | GenomeWeb

NEW YORK (GenomeWeb) – Illumina's second quarter revenues rose 21 percent year over year, the company announced after the close of the market on Tuesday, but fell short of Wall Street's consensus estimate on the top line.

The firm recognized total revenues of $539.4 million for the three months ended June 30, compared to $447.6 million in the second quarter 2014. Analysts, on average, had expected revenues of $541.8 million. On a constant currency basis, Illumina's revenues rose 25 percent.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: metagenomic-based technique for determining protein structure, and more.

An academic laments the rise of narcissism in the sciences, the Guardian reports.

Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.

The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.